SC1-HCO-03-2017: Implementing the Strategic Research Agenda on Personalised Medicine

Main pillar: 

  • Health, Demographic Change and Wellbeing



Call deadline: 

Mon, 11 Apr 2016


  • Forthcoming


Scope:Proposals should pool the necessary financial resources from the participating national (or regional) research programmes with a view to implementing a joint call for proposals resulting in grants to third parties with co-funding in this area.This call should aim at implementing a key area of the PerMed Strategic Research Agenda and be complementary with other funding programmes and activities at European and international level. Proposers are encouraged to include other joint activities including additional joint calls without EU co-funding. This work should be informed by the output of the coordination and support action envisaged in topic SC1-HCO-05-2016 - Coordinating personalised medicine research, without duplicating any of its work.The proposed ERA-NET should demonstrate the expected impact on national and transnational programmes as well as the leverage effect on European research and competitiveness, and should plan the development of key indicators for supporting this. Participation of international partners is highly encouraged.The Commission considers that a proposal requesting a contribution from the EU of EUR 5 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.Expected Impact:

  • Deepened and extended coordination of national and transnational research in the field of personalised medicine.
  • Streamlined national/regional and international practices in organising research funding.
  • Increased interoperability of national research programmes.
  • Increased sharing of data and knowledge.
  • Increased networking of infrastructures and databases such as ESFRI infrastructures

[1]Personalised medicine refers to a medical model using characterization of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention. The term "personalised medicine" is used throughout this Work Programme with this definition in mind.[2][3]Available at